General description
一种ATP竞争性的HGFR和VEGFR抑制剂,抑制Met和 KDR,IC50值分别为0.4 nM和0.9 nM.
Foretinib is an orally bioavailable small molecule with potential antineoplastic activity. MET/VEGFR2 inhibitor GSK1363089 binds to and selectively inhibits hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in the inhibition of tumor angiogenesis, tumor cell proliferation and metastasis. The proto-oncogene c-MET has been found to be over-expressed in a variety of cancers.
福瑞替尼是一种具有潜在抗肿瘤活性的生物利用小分子。 MET / VEGFR2抑制剂GSK1363089结合并选择性抑制肝细胞生长因子(HGF)受体c-MET和血管内皮生长因子受体2(VEGFR2),这可能导致肿瘤血管生成,肿瘤细胞增殖和转移受到抑制。 已经发现原癌基因c-MET在多种癌症中过表达。
Properties
Iupac Name: | N-(3-fluoro-4-(6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yloxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
Inchi Code | 1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42) |
Inchi Key | CXQHYVUVSFXTMY-UHFFFAOYSA-N |
安全信息